Loading stock data…
Cellectar Biosciences (CLRB)
$2.60+0.08 (+3.17%)
Market ClosedLast close Jun 29
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cellectar Biosciences, Inc. in the Healthcare sector is trading at $2.60 with a market capitalization of $18M. Wall Street consensus targets $10.33 (3 analysts), implying a +297.4% move over the next 12 months. The stock is currently near its 52-week low of $2.20, remaining 23.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +297.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.79M↓ | -$5.69M↓ | -$4.85M↑ | -$6.04M↑ | -$6.40M |
| Net Income | -$5.65M↓ | -$5.30M↓ | -$4.44M↑ | -$5.45M↑ | -$6.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-624.90%
Volume
Today's trading volume
184,362
Recent News
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Cellectar Biosciences Inc (CLRB) showcases promising clinical progress and strategic financing, despite ongoing financial hurdles.
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby summary of Cellectar Biosciences, Inc.'s Q1 2026 earnings call
Cellectar (CLRB) Q1 2026 Earnings Transcript
Anne Marie Fields: Thank you, Vanessa. Joining us today from Cellectar are Jim Caruso, President and CEO; who will provide an overview of the company's progress before turning the call over to Chad Cohen, CFO; for a financial review of the quarter. Following this, Jarrod Longcor, Chief Operating Officer; will give an update on the company's progress and plans for its promising clinical development pipeline of radiopharmaceuticals.
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia
Updated 12-month follow-up results may support regulatory progress for its lead oncology candidate. Cellectar Biosciences, Inc.